Your browser doesn't support javascript.
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.
Tur, Carmen; Dubessy, Anne-Laure; Otero-Romero, Susana; Amato, Maria Pia; Derfuss, Tobias; Di Pauli, Franziska; Iacobaeus, Ellen; Mycko, Marcin; Abboud, Hesham; Achiron, Anat; Bellinvia, Angelo; Boyko, Alexey; Casanova, Jean-Laurent; Clifford, David; Dobson, Ruth; Farez, Mauricio F; Filippi, Massimo; Fitzgerald, Kathryn C; Fonderico, Mattia; Gouider, Riadh; Hacohen, Yael; Hellwig, Kerstin; Hemmer, Bernhard; Kappos, Ludwig; Ladeira, Filipa; Lebrun-Frénay, Christine; Louapre, Céline; Magyari, Melinda; Mehling, Matthias; Oreja-Guevara, Celia; Pandit, Lekha; Papeix, Caroline; Piehl, Fredrik; Portaccio, Emilio; Ruiz-Camps, Isabel; Selmaj, Krzysztof; Simpson-Yap, Steve; Siva, Aksel; Sorensen, Per Soelberg; Sormani, Maria Pia; Trojano, Maria; Vaknin-Dembinsky, Adi; Vukusic, Sandra; Weinshenker, Brian; Wiendl, Heinz; Winkelmann, Alexander; Zuluaga Rodas, María Isabel; Tintoré, Mar; Stankoff, Bruno.
  • Tur C; Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Dubessy AL; Sorbonne Université, Inserm, CNRS, UMR7225, Institut du Cerveau et de la Moelle épinière (ICM), Paris, France/ Department of Neurology, Saint Antoine Hospital, AP-HP, Paris, France.
  • Otero-Romero S; Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Amato MP; Department of NEUROFARBA, University of Florence, Florence, Italy/IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.
  • Derfuss T; Neurology Clinic and Policlinic, Departments of Medicine, Clinical Research and Biomedicine and Research Center for Clinical Neuroimmunology and Neuroscience Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Di Pauli F; Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
  • Iacobaeus E; Division of Neurology, Department of Clinical Neuroscience, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
  • Mycko M; Department of Neurology, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.
  • Abboud H; Multiple Sclerosis and Neuroimmunology Program, University Hospitals of Cleveland, Case Western Reserve University School of Medicine, Cleveland Medical Center, Cleveland, OH, USA.
  • Achiron A; Sheba Medical Center at Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Bellinvia A; Department of NEUROFARBA, University of Florence, Florence, Italy.
  • Boyko A; Department of Neurology, Neurosurgery and Medical Genetics, Pirogov Russian National Research Medical University, Moscow, Russia/Institute of Clinical Neurology and Department of Neuroimmunology, Federal Center of Brain Research and Neurotechnologies, Moscow, Russia.
  • Casanova JL; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.
  • Clifford D; Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA.
  • Dobson R; Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK/Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, UK.
  • Farez MF; Center for Research on Neuroimmunological Diseases, FLENI, Buenos Aires, Argentina.
  • Filippi M; Neurology Unit, Neurorehabilitation Unit and Neurophysiology Service, IRCCS San Raffaele Scientific Institute, Milan, Italy/Vita-Salute San Raffaele University, Milan, Italy.
  • Fitzgerald KC; Department of Neurology and Epidemiology, Johns Hopkins University, Baltimore, MD, USA.
  • Fonderico M; Department of NEUROFARBA, University of Florence, Florence, Italy.
  • Gouider R; Department of Neurology, Razi Hospital, Tunis, Tunisia.
  • Hacohen Y; Department of Neuroinflammation, Queen Square Multiple Sclerosis Centre, UCL Institute of Neurology, London, UK.
  • Hellwig K; Department of Neurology, St. Josef Hospital, Ruhr-University Bochum, Bochum, Germany.
  • Hemmer B; Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
  • Kappos L; Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital, University of Basel, Basel, Switzerland.
  • Ladeira F; Neurology Department, Hospital Santo António dos Capuchos, Centro Hospitalar Universitário Lisboa Central, Lisbon, Portugal.
  • Lebrun-Frénay C; CRCSEP Côte d'Azur, CHU de Nice Pasteur 2, UR2CA-URRIS, Université Nice Côte d'Azur, Nice, France.
  • Louapre C; Sorbonne Université, Inserm, CNRS, UMR7225, Institut du Cerveau et de la Moelle épinière (ICM), Paris, France/Sorbonne University, Paris Brain Institute-ICM, Assistance Publique Hôpitaux de Paris, Inserm, CNRS, Hôpital de la Pitié Salpêtrière, CIC Neurosciences, Paris, France.
  • Magyari M; Department of Neurology, Danish Multiple Sclerosis Center, Copenhagen University Hospital, Copenhagen, Denmark.
  • Mehling M; Neurology Clinic and Policlinic, Departments of Medicine, Clinical Research and Biomedicine and Research Center for Clinical Neuroimmunology and Neuroscience Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Oreja-Guevara C; Department of Neurology, Hospital Clínico San Carlos, Idissc, Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.
  • Pandit L; Center for Advanced Neurological Research, KS Hegde Medical Academy, Nitte (Deemed to be University), Mangalore, India.
  • Papeix C; Sorbonne Université, Inserm, CNRS, UMR7225, Institut du Cerveau et de la Moelle épinière (ICM), Paris, France/Sorbonne University, Paris Brain Institute-ICM, Assistance Publique Hôpitaux de Paris, Inserm, CNRS, Hôpital de la Pitié Salpêtrière, CIC Neurosciences, Paris, France.
  • Piehl F; Division of Neurology, Department of Clinical Neuroscience, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
  • Portaccio E; Department of NEUROFARBA, University of Florence, Florence, Italy.
  • Ruiz-Camps I; Servicio de Enfermedades Infecciosas, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Selmaj K; Collegium Medicum, Department of Neurology, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland/Center of Neurology, Lodz, Poland.
  • Simpson-Yap S; Clinical Outcomes Research Unit, The Royal Melbourne Hospital, The University of Melbourne, Melbourne, VIC, Australia.
  • Siva A; Department of Neurology, Istanbul University Cerrahpasa School of Medicine, Istanbul, Turkey.
  • Sorensen PS; Department of Neurology, Danish Multiple Sclerosis Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Sormani MP; Department of Health Sciences, University of Genoa and IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • Trojano M; Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro," Bari, Italy.
  • Vaknin-Dembinsky A; Hadassah-Hebrew University Medical Center, Department of Neurology, The Agnes-Ginges Center for Neurogenetics Jerusalem, Jerusalem, Israel.
  • Vukusic S; Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France/Centre des Neurosciences de Lyon, Observatoire Français de la Sclérose en Plaques, INSERM 1028 et CNRS UMR5292, Lyon, France/Univ
  • Weinshenker B; Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Wiendl H; Department of Neurology with Institute of Translational Neurology, University of Muenster, Münster, Germany.
  • Winkelmann A; Department of Neurology, University of Rostock, Rostock, Germany.
  • Zuluaga Rodas MI; MS Clinic, Instituto Neurológico de Colombia and Medicarte, Medellin, Colombia.
  • Tintoré M; Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Stankoff B; Sorbonne Université, Inserm, CNRS, UMR7225, Institut du Cerveau et de la Moelle épinière (ICM), Paris, France/ Department of Neurology, Saint Antoine Hospital, AP-HP, Paris, France.
Mult Scler ; 28(9): 1424-1456, 2022 08.
Article in English | MEDLINE | ID: covidwho-1923462
ABSTRACT
Over the recent years, the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) has evolved very rapidly and a large number of disease-modifying treatments (DMTs) are now available. However, most DMTs are associated with adverse events, the most frequent of which being infections. Consideration of all DMT-associated risks facilitates development of risk mitigation strategies. An international focused workshop with expert-led discussions was sponsored by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and was held in April 2021 to review our current knowledge about the risk of infections associated with the use of DMTs for people with MS and NMOSD and corresponding risk mitigation strategies. The workshop addressed DMT-associated infections in specific populations, such as children and pregnant women with MS, or people with MS who have other comorbidities or live in regions with an exceptionally high infection burden. Finally, we reviewed the topic of DMT-associated infectious risks in the context of the current SARS-CoV-2 pandemic. Herein, we summarize available evidence and identify gaps in knowledge which justify further research.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Neuromyelitis Optica / COVID-19 / Multiple Sclerosis Type of study: Observational study / Prognostic study Limits: Child / Female / Humans / Pregnancy Language: English Journal: Mult Scler Journal subject: Neurology Year: 2022 Document Type: Article Affiliation country: 13524585211069068

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Neuromyelitis Optica / COVID-19 / Multiple Sclerosis Type of study: Observational study / Prognostic study Limits: Child / Female / Humans / Pregnancy Language: English Journal: Mult Scler Journal subject: Neurology Year: 2022 Document Type: Article Affiliation country: 13524585211069068